<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03410927</url>
  </required_header>
  <id_info>
    <org_study_id>TO-TAS0728-101</org_study_id>
    <secondary_id>2017-004415-39</secondary_id>
    <nct_id>NCT03410927</nct_id>
  </id_info>
  <brief_title>A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities</brief_title>
  <official_title>A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects With Advanced Solid Tumors With HER2 or HER3 Abnormalities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a First-in-Human (FIH), 2-part, Phase 1/2, open-label, multicenter study design to
      evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of TAS0728. This
      study consists of Phase 1 and Phase 2a components in subjects with advanced solid tumors with
      HER2 or HER3 overexpression, amplification, or mutation who have progressed despite standard
      therapy or for which no standard therapy exists, particularly urothelial cancer, biliary
      tract cancer, metastatic breast cancer, non-small cell lung cancer and colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>In Phase 1, TAS0728 will be evaluated for safety and tolerability, and in phase 2a will be evaluated preliminary efficacy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients experiencing Dose Limiting Toxicity graded according to CTCAE Version 4.03, observed in the Cycle 1 in order to meet the objective of assessment of the MTD of TAS0728.</measure>
    <time_frame>21-day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (Phase 1 and 2a)</measure>
    <time_frame>Safety monitoring will begin at the informed consent obtained and continue up to 30 days after the last dose of TAS0728 or until new antitumor therapy, whichever is earlier.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST) (Phase2a)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) after administration of TAS0728 (Phase 1)</measure>
    <time_frame>21 days in Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma drug concentration-time curve (AUC) after administration of TAS0728 (Phase 1)</measure>
    <time_frame>21 days in Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate using RECIST 1.1 (phase 1 and 2a)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (phase 1 and 2a)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (phase 1 and 2a)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (phase 1 and 2a)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>HER2 Abnormalities</condition>
  <condition>HER3 Abnormalities</condition>
  <arm_group>
    <arm_group_label>TAS0728</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: Urothelial cancer with HER2 or HER3 mutation Group 2: Biliary tract cancer with HER2 or HER3 mutation Group 3: Breast cancer with HER2 or HER3 mutation Group 4: Breast cancer with HER2 amplification or overexpression as per American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) 2013 guidelines Group 5: Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Group 6: Colorectal cancer (CRC) with HER2 mutation or amplification Group 7: Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS0728</intervention_name>
    <description>TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.</description>
    <arm_group_label>TAS0728</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or females with an age â‰¥ 18 years.

          2. Subjects with histological- or cytological-confirmed, advanced cancer, who have
             progressed on (or not been able to tolerate) standard therapy or for whom no standard
             anticancer therapy exists

               1. For Phase 1, only subjects HER2 or HER3 molecular/genetic alterations will be
                  enrolled.

               2. For Phase 2a, subjects with one of the following tumor types will be enrolled:

             i. Urothelial cancer with HER2 or HER3 mutation ii. Biliary tract cancer with HER2 or
             HER3 mutation iii. Breast cancer with HER2 or HER3 mutation iv. Breast cancer with
             HER2 amplification or overexpression v. NSCLC with HER2 or HER3 mutation vi. CRC with
             HER2 mutation or amplification vii. Other tumors with HER2
             mutation/amplification/overexpression or HER3 mutation (gastric/GEJ, endometrial).

          3. At least 1 measurable lesion for solid tumor

          4. Is able to take medications orally (e.g., no feeding tube).

          5. Able to agree to and sign informed consent and to comply with the protocol

          6. Has adequate organ function

        Exclusion Criteria:

          1. Has a serious illness or medical condition(s)

          2. Has received treatment with any proscribed treatments within specified time frames
             prior to study drug administration

          3. Impaired cardiac function or clinically significant cardiac disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Kirshbaum, MD</last_name>
    <phone>609-750-5300</phone>
    <email>MKirschbaum@taihooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Kirschbaum, MD</last_name>
      <phone>609-750-5300</phone>
      <email>MKirschbaum@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Kirschbaum, MD</last_name>
      <phone>609-750-5300</phone>
      <email>MKirschbaum@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Kirschbaum, MD</last_name>
      <phone>609-750-5300</phone>
      <email>MKirschbaum@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Gustavo Roussy</name>
      <address>
        <city>Paris</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Hollebecque, MD</last_name>
      <phone>+33 142 114 385</phone>
      <email>Antoine.hollebecque@gustaveroussy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D'hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josep Tabernero, MD</last_name>
      <phone>+34 93 274 6085</phone>
      <email>itabernero@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - UK</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hendrick-Tobias Arkenau, MD</last_name>
      <phone>+02 03 219 5200</phone>
      <email>Tobias.Arkenau@HCAHealthcare.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2018</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>solid tumors</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>MTD</keyword>
  <keyword>TAS0728</keyword>
  <keyword>HER2</keyword>
  <keyword>HER3 mutation</keyword>
  <keyword>amplification or overexpression</keyword>
  <keyword>Urothelial cancer with HER2 or HER3 mutation</keyword>
  <keyword>Biliary tract cancer with HER2 or HER3 mutation</keyword>
  <keyword>MBC with HER2 amplification or overexpression or HER3 mutation</keyword>
  <keyword>NSCLC with HER2 or HER3 mutation</keyword>
  <keyword>CRC with HER2 or HER3 mutation</keyword>
  <keyword>amplification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

